Sensyne Health signs agreements to launch digital health products in US
Sensyne, MHRA form research collaboration
UK AI firm Sensyne makes inroads into US health market
Sensyne Health Lauds Strong Progress As Maiden Loss Deepens On Costs
Sensyne Health: maiden results and new partnerships
Sensyne Health books annual loss as R&D spending rises; forms US partnerships
Ex-Science Minister Drayson warns over foreign 'colonisation' of NHS
AI in the clinic opens new vistas for biopharma investigators
Bayer in deal to search U.K. NHS data for heart drug clues
Sensyne Health Partners with Bayer to Accelerate New Treatments for Cardiovascular Disease
Bayer, Sensyne to use AI platform to accelerate CV development
Clinical AI firm Sensyne partnering with Bayer to improve cardiovascular trials
Sensyne Health, Bayer collaborate on new AI-powered treatments for heart disease
How we can place a value on healthcare data
AI firm Sensyne Health signs £5m agreement with Bayer
Bayer teams up with AI firm Sensyne Health to mine NHS data for its heart disease pipeline
© 2019 Sensyne Health plc. All rights reserved.
Sensyne Health Group Limited. registered in England and Wales No. 11240986 is a trading company of Sensyne Health plc registered in England and Wales No. 11425451
Registered office: Schrödinger Building, Heatley Road, Oxford Science Park, Oxford, OX4 4GE, United Kingdom.
Note: Not all Sensyne Health products are available in all geographies, for further information contact head office.